Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 13.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,431,911 shares of the company’s stock after acquiring an additional 656,003 shares during the period. Geode Capital Management LLC owned about 1.93% of Recursion Pharmaceuticals worth $35,803,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Barclays PLC increased its stake in shares of Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock worth $4,596,000 after buying an additional 244,278 shares during the period. Wellington Management Group LLP acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $692,000. State Street Corp increased its position in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of Recursion Pharmaceuticals by 48.8% in the 3rd quarter. Stifel Financial Corp now owns 161,978 shares of the company’s stock valued at $1,067,000 after purchasing an additional 53,103 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its position in shares of Recursion Pharmaceuticals by 13,196.3% during the 3rd quarter. Benjamin Edwards Inc. now owns 162,481 shares of the company’s stock worth $1,071,000 after purchasing an additional 161,259 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $7.24 on Thursday. The company has a fifty day moving average of $6.78 and a two-hundred day moving average of $7.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The company has a market capitalization of $2.08 billion, a PE ratio of -4.73 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the business earned ($0.43) EPS. The company’s quarterly revenue was up 147.6% compared to the same quarter last year. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RXRX. Jefferies Financial Group cut their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Leerink Partners cut their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9.25.

Insider Activity

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,788 shares of company stock valued at $682,691 in the last ninety days. 15.75% of the stock is currently owned by company insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.